Cargando…

British Cancer Research Meeting, 30 June-3 July 2002, Glasgow

The 2002 British Cancer Research Meeting was held from 30th June to 3rd July in Glasgow, UK. The meeting was structured to include educational workshops, plenary lectures, symposia, and poster sessions, which brought together scientists and clinicians. Presentations ranged from the impact that modif...

Descripción completa

Detalles Bibliográficos
Autores principales: Parkes, Alicia T, Speirs, Valerie
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138745/
https://www.ncbi.nlm.nih.gov/pubmed/12223125
_version_ 1782120488056651776
author Parkes, Alicia T
Speirs, Valerie
author_facet Parkes, Alicia T
Speirs, Valerie
author_sort Parkes, Alicia T
collection PubMed
description The 2002 British Cancer Research Meeting was held from 30th June to 3rd July in Glasgow, UK. The meeting was structured to include educational workshops, plenary lectures, symposia, and poster sessions, which brought together scientists and clinicians. Presentations ranged from the impact that modifications to basic chromatin structure can have on diagnosis and targeted gene therapy, to the outcome of novel therapeutics through clinical trials. The emphasis was clear: patient survival is the main priority and treatment of organ-specific cancer must inevitably be replaced by individualised tumour-specific therapy.
format Text
id pubmed-138745
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1387452003-02-27 British Cancer Research Meeting, 30 June-3 July 2002, Glasgow Parkes, Alicia T Speirs, Valerie Breast Cancer Res Meeting Report The 2002 British Cancer Research Meeting was held from 30th June to 3rd July in Glasgow, UK. The meeting was structured to include educational workshops, plenary lectures, symposia, and poster sessions, which brought together scientists and clinicians. Presentations ranged from the impact that modifications to basic chromatin structure can have on diagnosis and targeted gene therapy, to the outcome of novel therapeutics through clinical trials. The emphasis was clear: patient survival is the main priority and treatment of organ-specific cancer must inevitably be replaced by individualised tumour-specific therapy. BioMed Central 2002 2002-07-29 /pmc/articles/PMC138745/ /pubmed/12223125 Text en Copyright © 2002 BioMed Central Ltd
spellingShingle Meeting Report
Parkes, Alicia T
Speirs, Valerie
British Cancer Research Meeting, 30 June-3 July 2002, Glasgow
title British Cancer Research Meeting, 30 June-3 July 2002, Glasgow
title_full British Cancer Research Meeting, 30 June-3 July 2002, Glasgow
title_fullStr British Cancer Research Meeting, 30 June-3 July 2002, Glasgow
title_full_unstemmed British Cancer Research Meeting, 30 June-3 July 2002, Glasgow
title_short British Cancer Research Meeting, 30 June-3 July 2002, Glasgow
title_sort british cancer research meeting, 30 june-3 july 2002, glasgow
topic Meeting Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138745/
https://www.ncbi.nlm.nih.gov/pubmed/12223125
work_keys_str_mv AT parkesaliciat britishcancerresearchmeeting30june3july2002glasgow
AT speirsvalerie britishcancerresearchmeeting30june3july2002glasgow